Imagion Biosystems Limited has released the Renounceable Rights Issue Prospectus:
For a renounceable pro rata offer of 204,512,879 Shares at an issue price of $0.01 each on the basis of 2 Shares for every 5 Shares held at the Record Date, together with a free attaching New Option on a one for one basis, to raise up to $2,045,129, partially underwritten to $500,000.
Read the Renounceable Rights Issue Prospectus.
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance